Join us on April 30th for our 2025 Global Food & Beverage Project Spending Outlook! RSVP Today!
Sales & Support: +1 800 762 3361
Member Resources
Novo Nordisk Spends $11 Billion to Make More Weight Loss Drugs

GALWAY, IRELAND--February 15, 2024--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Danish pharmaceutical company Novo Nordisk is capitalizing on the unprecedented success of its diabetes and weight loss drugs by agreeing to pay US$11 billion to acquire three new production plants in Europe and the U.S. Within this article: Details purchase of three plants from Catalent to boost global supplies of diabetes and anti-obesity products Ozempic and Wegovy, locations, state of the market, related investments

Login or Register for Instant Access

Subscribe Now!

(All Fields Required)

IIR Logo Globe

Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.

×
×
Contact Us

For More Info!